Arindam Dhar

1.7k total citations
35 papers, 903 citations indexed

About

Arindam Dhar is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Arindam Dhar has authored 35 papers receiving a total of 903 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Arindam Dhar's work include Protein Degradation and Inhibitors (12 papers), Multiple Myeloma Research and Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Arindam Dhar is often cited by papers focused on Protein Degradation and Inhibitors (12 papers), Multiple Myeloma Research and Treatments (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Arindam Dhar collaborates with scholars based in United States, Spain and United Kingdom. Arindam Dhar's co-authors include Nancy H. Colburn, Mathew R. Young, Thierry Horner, Geoffrey I. Shapiro, Christopher A. French, Steven G. DuBois, Valentina Nardi, Robert I. Haddad, Stephen E. Sallan and Christopher S. Lathan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Arindam Dhar

35 papers receiving 895 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arindam Dhar United States 12 595 225 135 123 117 35 903
Xi Huang China 17 340 0.6× 199 0.9× 107 0.8× 102 0.8× 139 1.2× 45 711
Dominique Lautier France 16 624 1.0× 333 1.5× 68 0.5× 142 1.2× 108 0.9× 29 966
Darren C. Phillips United States 16 658 1.1× 210 0.9× 83 0.6× 239 1.9× 206 1.8× 40 1.1k
Tim Kute United States 9 326 0.5× 110 0.5× 114 0.8× 192 1.6× 89 0.8× 9 752
Yoko Hirabayashi Japan 14 443 0.7× 167 0.7× 136 1.0× 125 1.0× 206 1.8× 38 862
Filippa Pettersson Canada 18 654 1.1× 220 1.0× 96 0.7× 73 0.6× 90 0.8× 26 884
Juan Moreno‐Rubio Spain 19 634 1.1× 288 1.3× 393 2.9× 34 0.3× 86 0.7× 35 1.1k
Nobuhiko Harada Japan 19 531 0.9× 361 1.6× 132 1.0× 85 0.7× 84 0.7× 69 1.2k
Jeong‐Hun Ko United Kingdom 14 467 0.8× 131 0.6× 100 0.7× 50 0.4× 189 1.6× 23 781
Joanne S. Finch United States 17 563 0.9× 286 1.3× 303 2.2× 30 0.2× 82 0.7× 24 912

Countries citing papers authored by Arindam Dhar

Since Specialization
Citations

This map shows the geographic impact of Arindam Dhar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arindam Dhar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arindam Dhar more than expected).

Fields of papers citing papers by Arindam Dhar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arindam Dhar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arindam Dhar. The network helps show where Arindam Dhar may publish in the future.

Co-authorship network of co-authors of Arindam Dhar

This figure shows the co-authorship network connecting the top 25 collaborators of Arindam Dhar. A scholar is included among the top collaborators of Arindam Dhar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arindam Dhar. Arindam Dhar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davar, Diwakar, Zeynep Eroglu, Mohammed Milhem, et al.. (2025). Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B. Clinical Cancer Research. 31(16). 3443–3451. 1 indexed citations
2.
Davar, Diwakar, Zeynep Eroglu, Niranjan Yanamandra, et al.. (2025). Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A. Clinical Cancer Research. 31(16). 3433–3442. 2 indexed citations
3.
4.
Davar, Diwakar, Zeynep Eroglu, Mohammed Milhem, et al.. (2023). 596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy. SHILAP Revista de lepidopterología. A678–A678. 3 indexed citations
5.
Cescon, David W., John Hilton, Serafín Morales, et al.. (2023). A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 30(2). 334–343. 10 indexed citations
6.
Dhar, Arindam, et al.. (2021). Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors. CPT Pharmacometrics & Systems Pharmacology. 11(5). 556–568. 3 indexed citations
7.
Cousin, Sophie, Jean‐Yves Blay, Irene García, et al.. (2020). BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.. Journal of Clinical Oncology. 38(15_suppl). 3618–3618. 5 indexed citations
8.
Chau, Nicole G., Clement Ma, Hasan Al‐Sayegh, et al.. (2019). An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectrum. 4(2). pkz094–pkz094. 131 indexed citations
9.
Yap, Timothy A., Jane N. Winter, Lisa Giulino‐Roth, et al.. (2019). Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical Cancer Research. 25(24). 7331–7339. 128 indexed citations
10.
Bauer, Todd M., Benjamin Besse, Alex Martínez‐Martí, et al.. (2019). Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. Journal of Thoracic Oncology. 14(10). 1828–1838. 61 indexed citations
11.
12.
Gadgeel, Shirish M., Vicki L. Keedy, S. Taylor, et al.. (2017). Abstract CT104: A first-in-human phase I dose escalation study of BET inhibitor GSK2820151 in patients with advanced or recurrent solid tumors cancers. Cancer Research. 77(13_Supplement). CT104–CT104. 3 indexed citations
13.
Moreno, Víctor, Todd M. Bauer, Jon Infante, et al.. (2016). A phase I, open-label, study of GSK2879552, a lysine-specific demethylase 1 (LSD1) inhibitor, in patients with relapsed/refractory small cell lung carcinoma (SCLC). Annals of Oncology. 27. vi121–vi121. 1 indexed citations
14.
O’Dwyer, Peter J., Sarina A. Piha‐Paul, Christopher A. French, et al.. (2016). Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers. Cancer Research. 76(14_Supplement). CT014–CT014. 26 indexed citations
15.
16.
Amin, Asim, Marc S. Ernstoff, Jeffrey R. Infante, et al.. (2013). A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 31(15_suppl). TPS4593–TPS4593. 19 indexed citations
17.
Hammers, Hans J., Brian I. Rini, Gary R. Hudes, et al.. (2012). A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 30(15_suppl). TPS2614–TPS2614. 1 indexed citations
18.
Syed, S., Pamela L. Clemens, Deanne Lathers, et al.. (2011). Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, Administered Intravenously and Orally in Healthy Participants. The Journal of Clinical Pharmacology. 52(6). 914–921. 5 indexed citations
19.
Chu, Quincy, Peter Ellis, Linda Mileshkin, et al.. (2010). 412 BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors. European Journal of Cancer Supplements. 8(7). 131–131. 2 indexed citations
20.
Dhar, Arindam, Jing Hu, Raymond Reeves, Linda Resar, & Nancy H. Colburn. (2004). Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene. 23(25). 4466–4476. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xi Huang Breakdown of academic impact, for papers by Dominique Lautier Breakdown of academic impact, for papers by Darren C. Phillips Breakdown of academic impact, for papers by Tim Kute Breakdown of academic impact, for papers by Yoko Hirabayashi Breakdown of academic impact, for papers by Filippa Pettersson Breakdown of academic impact, for papers by Juan Moreno‐Rubio Breakdown of academic impact, for papers by Nobuhiko Harada Breakdown of academic impact, for papers by Jeong‐Hun Ko Breakdown of academic impact, for papers by Joanne S. Finch
Rankless by CCL
2026